J. V. van Lier

发表

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

A. Johne, H. Scheible, A. Becker, 2020, Investigational New Drugs.

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

X. Tong, R. D. de Knegt, H. Janssen, 2010, Hepatology.

Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge

J. V. van Lier, J. Stangier, J. Jonkman, 2001, Journal of cardiovascular pharmacology.

Absorption, metabolism and excretion of a single oral dose of 14C-repaglinide during repaglinide multiple dosing

J. V. van Lier, J. Jonkman, J. Jonkman, 1999, European Journal of Clinical Pharmacology.

Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

M. Zdravkovic, I. Bjørnsdottir, J. V. van Lier, 2010, Drug Metabolism and Disposition.

Pharmacokinetic drug interaction studies with candesartan cilexetil.

R. Lins, J. V. van Lier, J. Jonkman, 1997, Journal of human hypertension.

The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.

D. Smith, Deborah A. Smith, E. Seaber, 1998, British journal of clinical pharmacology.

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

A. Port, H. Scheible, J. V. van Lier, 2021, Clinical and translational science.

Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.

T. Hua, J. Barrett, H. Pieniaszek, 2001, Thrombosis research.

Metabolism and disposition of the αv‐integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

A. Kovar, A. Johne, H. Scheible, 2015, Journal of clinical pharmacology.

B-Z transition in methylated DNA. A quantum-chemical study.

H. Buck, J. V. van Lier, M. Smits, 1983, European journal of biochemistry.

Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P1 receptor modulator in healthy subjects

J. V. van Lier, J. Dingemanse, M. Ufer, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

An evaluation of human ADME and mass balance studies using regular or low doses of radiocarbon.

J. V. van Lier, S. van Marle, A. Roffel, 2016, Journal of labelled compounds & radiopharmaceuticals.

Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers

J. V. van Lier, B. Roubert, F. Dürrenberger, 2019, American journal of hematology.

Absorption, metabolism and excretion of the GLP‐1 analogue semaglutide in humans and nonclinical species

P. J. Pedersen, J. V. van Lier, H. Helleberg, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Lack of effect of amisulpride on the pharmacokinetics and safety of lithium.

C. Coulouvrat, M. Canal, E. Legangneux, 2003, The international journal of neuropsychopharmacology.

Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers.

J. V. van Lier, M. Sunzel, P. V. van Heiningen, 1997, Journal of human hypertension.

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

F. Raffi, C. Michelet, G. Fätkenheuer, 2007, AIDS.

Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects

J. V. van Lier, J. Dingemanse, M. Ufer, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers

M. Nagata, W. Krauwinkel, M. van Gelderen, 2012, Drug Metabolism and Disposition.

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

X. Tong, R. D. de Knegt, H. Janssen, 2010, Hepatology.